ImmunoPrecise Antibodies Ltd (NAS:IPA)

$ 0.77 -0.0233 (-2.94%) Market Cap: 21.02 Mil Enterprise Value: 28.68 Mil PE Ratio: 0 PB Ratio: 0.84 GF Score: 53/100

Q3 2024 Immunoprecise Antibodies Ltd Earnings Call Transcript
Mar 14, 2024

$1.59 (-2.45%)

Earnings
Q2 2024 Immunoprecise Antibodies Ltd Earnings Call Transcript
Dec 14, 2023

$1.45 (+20.83%)

Earnings
Q1 2024 Immunoprecise Antibodies Ltd Earnings Call Transcript
Sep 14, 2023

$2 (-0.99%)

Earnings
Immunoprecise Antibodies Ltd To Participate in an Interview Hosted by Market Radius Research Transcript
Jul 19, 2023
Q4 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Jul 07, 2023

$2.99 (-1.32%)

Earnings
Immunoprecise Antibodies Ltd at Smallcap Discoveries Transcript
Jun 28, 2023
Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q3 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Mar 16, 2023

$3.37 (-10.13%)

Earnings
Q2 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Dec 15, 2022

$4.9 (-8.58%)

Earnings
Q1 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Sep 14, 2022

$4.85 (-9.85%)

Earnings
Q4 2022 Immunoprecise Antibodies Ltd Earnings Call Transcript
Jul 29, 2022

$4.23 (-7.03%)

Earnings
Q2 2022 Immunoprecise Antibodies Ltd Earnings Call Transcript
Dec 13, 2021

$5.06 (-9.96%)

Earnings
Immunoprecise Antibodies Ltd LifeScience Webinar Transcript
Apr 28, 2021

Immunoprecise Antibodies Ltd LifeScience Webinar Transcript

Apr 28, 2021 / NTS GMT

Release Date Price: $9.72 (+3.85%)

Transcript

Unidentified Participant

Good afternoon, and welcome back, everyone at the LifeScience online days. We are here with Ilse Roodink from ImmunoPrecise Antibodies. And she'll be telling you more about how therapeutic antibodies can help us against SARS-CoV-2, and her colleague, Debby Kruijsen, is also here as a Moderator. So please don't hesitate to ask your questions in the chats. Please go ahead, Ilse.

Ilse Roodink

ImmunoPrecise Antibodies Ltd. - Scientific Director

Thank you. Dear attendees, thank you for taking the time to learn more about IPA SARS-CoV-2 therapeutic antibody program and our capabilities that underpin the identification of synergistic antibody cocktails targeting the spike glycoprotein.

I would also like to thanks, Sartorius, for giving us the opportunity to discuss in more detail how we're leveraging our multi-species antibody discovery platforms and high-throughput antibody characterization abilities businesses enabled us to formulate sensible therapeutic portfolios at an early stage. Thank you, Helena, for the introduction.

This is

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.